albany molecular research

Albany Molecular Research, Inc. (NASDAQ: AMRI), a drug discovery, development and manufacturing services company, announced on Thursday it has entered into a new agreement with Icagen. Icagen partners with pharmaceutical and biotechnology companies to offer industry-leading scientific expertise...

According to Jefferies, Albany Molecular Rsrch (NASDAQ: AMRI) continues to focus on growth opportunities outside the U.S. while recapturing business at home. Jefferies said that Allegra royalties got a significant boost but not enough to produce a profitable quarter. “Issues surrounding the...

Jefferies finds Albany Molecular Research's (NASDAQ: AMRI) “continued reliance on declining Allegra royalties makes profit growth difficult. An OTC conversion will extend the stream, but won't convert it to a growth driver.” The report further adds, “AMRI reported a non-GAAP 4Q loss of $0.16 on...

Jefferies & Company has lowered the price target on Albany Molecular Research (NASDAQ: AMRI) from $5.50 to $4.50 and maintains its Hold rating.